Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy

Monika Simmons*, Timothy Burgess, Julia Lynch, Robert Putnak

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

79 Scopus citations

Abstract

A new vaccination strategy for dengue virus (DENV) was evaluated in rhesus macaques by priming with tetravalent purified inactivated virus (TPIV) or tetravalent plasmid DNA vaccines expressing the structural prME gene region (TDNA) then boosting 2 months later with a tetravalent live attenuated virus (TLAV) vaccine. Both vaccine combinations elicited virus neutralizing (N) antibodies. The TPIV/TLAV combination afforded complete protection against DENV 3 challenge at month 8. In a second experiment, priming with TPIV elicited N antibodies against all four serotypes (GMT 1:28 to 1:43). Boosting with TLAV led to an increase in the GMT for each serotype (1:500 to 1:1200 for DENVs 1, 3, and 4, and greater than 1:6000 for DENV 2), which declined by month 8 (GMT 1:62 for DENV 3, 1:154 for DENV 1, 1:174 for DENV 4, and 1:767 for DENV 2). After challenge with each one of the four DENV serotypes, vaccinated animals exhibited no viremia but showed anamnestic antibody responses to the challenge viruses.

Original languageEnglish
Pages (from-to)280-288
Number of pages9
JournalVirology
Volume396
Issue number2
DOIs
StatePublished - 20 Jan 2010

Keywords

  • Dengue DNA
  • Live attenuated virus
  • Prime boost
  • Purified inactivated virus

Fingerprint

Dive into the research topics of 'Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy'. Together they form a unique fingerprint.

Cite this